Skip to main content

Table 1 Main characteristics of the studied children

From: Differentially methylated CpGs in response to growth hormone administration in children with idiopathic short stature

 

Mean ± SD

N

47

Sex (M/F)

23/24

Age at rhGH onset (year)

9.8 ± 1.8

Tanner stage (stage 0/stage 1)

36/11

Mean rhGH dose (µg/kg day)

70.8 ± 19

Treatment duration (months)

18.1 ± 7.3

Growth rate before treatment (cm/year)

4.6 ± 1.0

Growth rate during treatment (cm/year)

9.1 ± 1.5

Plasma IGF1 at baseline (ng/ml)

167 ± 80

Mean IGF1during treatment (ng/ml)

402 ± 123

Delta IGF1 under treatment (ng/ml)

235 ± 117